Cip/Kip proteins that inhibit cyclin-dependent kinase 2 (Cdk2) restrain the initiation of DNA replication. Degradation of a Xenopus Kip1 orthologue, Xic1, is dependent on its recruitment to ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which ...

Cyclins regulate steroid receptor action in cyclin-dependent kinase (CDK)-dependent and independent manners. In addition to regulating the cell cycle, cyclin A2 (CCNA2) also mediates female sex ...

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of ...

An injectable hydrogel platform shows promise in local immunotherapy for triple-negative breast cancer, enhancing treatment ...

Ryvu Therapeutics has initiated the Phase II trial, POTAMI-61, dosing the first subject with a small-molecule cyclin-dependent kinase (CDK) 8/19 inhibitor, RVU120, for treating myelofibrosis (MF).

Equities research analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a report issued on Sunday. The brokerage set a “sell” rating on ...